2021-01-05,Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
2020-12-29,Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
2020-12-29,Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
2020-12-22,Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
2020-12-10,"Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH"
2020-12-02,Hepion Pharmaceuticals CRV431 Demonstrates Additional Potential Advantage in Liver Disease
2020-11-30,Hepion Announces Closing of Public Offering of Common Stock
2020-11-30,Penny Stocks to Buy Using Technical Analysis for December 2020
2020-11-24,Hepion Pharmaceuticals Prices Public Offering
2020-11-18,Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
2020-11-17,Hepion Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
2020-11-12,Hepion Pharmaceuticals to Present at The Liver Meeting Digital Experience(TM) 2020
2020-11-10,Hepion Pharmaceuticals Completes First Cohort Enrollment in Phase 2a 'AMBITION' Clinical Trial
2020-11-05,Is Hepion Pharmaceuticals (NASDAQ:HEPA) In A Good Position To Invest In Growth?
2020-10-27,"Hepion Pharmaceuticals to Present on Therapeutic Approaches to COVID-19 and NASH at Two Virtual Conferences on October 28 and 29, 2020"
2020-10-05,Hepion Pharmaceuticals Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team
2020-09-29,Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
2020-09-17,Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases
2020-09-01,Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
2020-08-27,Hepion Pharmaceuticals to Present CRV431 Preclinical Data at the 2020 Digital International Liver Congress(TM)
2020-08-12,Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431's Antiviral Properties
2020-08-05,Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 'AMBITION' Clinical Trial
2020-07-07,Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
2020-06-29,Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
2020-06-22,Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis
2020-06-10,"Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors"
2020-05-20,Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
2020-05-19,Hepion Pharmaceuticals' CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis
2020-03-12,Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study
2020-02-19,Anti-Fibrotic Activity of Hepion Pharmaceuticals CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases
2020-02-12,Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
2020-01-28,"Hepions NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study"
2020-01-08,Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference
2020-01-06,Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs
2019-12-23,"Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII"
2019-12-12,"Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF"
2019-12-11,Buy These 5 Stocks as New Analysts Initiate Coverage
2019-12-10,Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
2019-12-09,Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019
2019-12-03,Hepion Pharmaceuticals Announces Canadian Research Teams Academic Appointments
2019-12-03,Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
2019-11-21,Hepion Rips Higher After NASH Drug Confirms Antifibrotic Activity In Animal Study
2019-11-21,Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment
2019-11-20,Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
2019-11-07,Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019
2019-11-07,Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH
2019-10-23,Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit
2019-10-16,Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases
2019-10-10,"World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director"
2019-10-03,Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions
2019-09-04,Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference
2019-09-03,Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
2019-08-14,Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431
2019-08-07,Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
2019-07-31,"Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta"
